Loading…
Astragaloside IV ameliorates metabolic disorder in db/db obese mice as a PPARγ antagonist
Metabolic disorder is highly related to obesity, insulin resistance, hypertension, and hyperlipidemia. The present study found that astragaloside IV (ASI) attenuated metabolic disorder related symptoms and modulated hepatic lipid metabolism associated gene mRNA expression in db/db mice. ASI inhibite...
Saved in:
| Published in: | Journal of asian natural products research 2023-05, Vol.25 (5), p.484-496 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c394t-db3b7943217fe76a77aa91453a0f44355dd07bb33506a1f8336fa3e8ead78eb93 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c394t-db3b7943217fe76a77aa91453a0f44355dd07bb33506a1f8336fa3e8ead78eb93 |
| container_end_page | 496 |
| container_issue | 5 |
| container_start_page | 484 |
| container_title | Journal of asian natural products research |
| container_volume | 25 |
| creator | Wu, Hui Wang, Gao-Rui Wang, Xin-Ting Bai, Yu-Yan Yuan, Jin-Feng Yang, Liu Huang, Fei Shi, Hai-Lian Wu, Xiao-Jun |
| description | Metabolic disorder is highly related to obesity, insulin resistance, hypertension, and hyperlipidemia. The present study found that astragaloside IV (ASI) attenuated metabolic disorder related symptoms and modulated hepatic lipid metabolism associated gene mRNA expression in db/db mice. ASI inhibited rosiglitazone-induced adipocyte differentiation of 3T3-L1 cells, and lipid accumulation in palmitic acid (PA)-induced HepG2 cells with down-regulated mRNA expression of lipogenesis-related genes. In addition, it was predicted to bind to the ligand binding domain (LBD) of PPARγ and inhibit its transactivity. Collectively, our study suggested that ASI improves lipid metabolism in obese mice probably through suppressing PPARγ activity. |
| doi_str_mv | 10.1080/10286020.2022.2098726 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_proquest_journals_2799929978</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2799929978</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-db3b7943217fe76a77aa91453a0f44355dd07bb33506a1f8336fa3e8ead78eb93</originalsourceid><addsrcrecordid>eNp9kM9q3DAQh0Voaf71EVIEvfTiRNLYknXrEtokEGgoTQ-9iJE1Dgq2lUpeSp4r79Fnipfd9JBDLzNz-H4zw8fYiRSnUrTiTArVaqHEqRJKLcW2Ruk9diBrYyqlJLxZ5oWpNtA-OyzlXgglpVbv2D40rdaqFgfs16rMGe9wSCUG4lc_OY40xJRxpsJHmtGnIXY8xJJyoMzjxIM_C54nT4X4GDviWDjym5vV979PHKcZ79IUy3zM3vY4FHq_60fs9uuXH-eX1fW3i6vz1XXVga3nKnjwxtagpOnJaDQG0cq6ARR9XUPThCCM9wCN0Cj7FkD3CNQSBtOSt3DEPm33PuT0e01ldmMsHQ0DTpTWxSltwRgA2S7ox1fofVrnafnOKWOtVdaaDdVsqS6nUjL17iHHEfOjk8Jt5LsX-W4j3-3kL7kPu-1rP1L4l3qxvQCft0Cc-pRH_JPyENyMj0PKfcapi8XB_288A7XEkmw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2799929978</pqid></control><display><type>article</type><title>Astragaloside IV ameliorates metabolic disorder in db/db obese mice as a PPARγ antagonist</title><source>Taylor and Francis Science and Technology Collection</source><creator>Wu, Hui ; Wang, Gao-Rui ; Wang, Xin-Ting ; Bai, Yu-Yan ; Yuan, Jin-Feng ; Yang, Liu ; Huang, Fei ; Shi, Hai-Lian ; Wu, Xiao-Jun</creator><creatorcontrib>Wu, Hui ; Wang, Gao-Rui ; Wang, Xin-Ting ; Bai, Yu-Yan ; Yuan, Jin-Feng ; Yang, Liu ; Huang, Fei ; Shi, Hai-Lian ; Wu, Xiao-Jun</creatorcontrib><description>Metabolic disorder is highly related to obesity, insulin resistance, hypertension, and hyperlipidemia. The present study found that astragaloside IV (ASI) attenuated metabolic disorder related symptoms and modulated hepatic lipid metabolism associated gene mRNA expression in db/db mice. ASI inhibited rosiglitazone-induced adipocyte differentiation of 3T3-L1 cells, and lipid accumulation in palmitic acid (PA)-induced HepG2 cells with down-regulated mRNA expression of lipogenesis-related genes. In addition, it was predicted to bind to the ligand binding domain (LBD) of PPARγ and inhibit its transactivity. Collectively, our study suggested that ASI improves lipid metabolism in obese mice probably through suppressing PPARγ activity.</description><identifier>ISSN: 1028-6020</identifier><identifier>EISSN: 1477-2213</identifier><identifier>DOI: 10.1080/10286020.2022.2098726</identifier><identifier>PMID: 35866240</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>3T3-L1 Cells ; Animals ; Astragaloside IV ; Cell differentiation ; db/db mice ; Gene expression ; Hyperlipidemia ; Hypertension ; Insulin ; Insulin resistance ; Lipid metabolism ; Lipids ; Lipogenesis ; metabolic disorder ; Metabolic disorders ; Mice ; Mice, Inbred C57BL ; Mice, Obese ; Obesity ; Obesity - drug therapy ; Obesity - metabolism ; Palmitic acid ; Peroxisome proliferator-activated receptors ; PPAR gamma - genetics ; PPAR gamma - metabolism ; PPARγ ; RNA, Messenger ; Rosiglitazone</subject><ispartof>Journal of asian natural products research, 2023-05, Vol.25 (5), p.484-496</ispartof><rights>2022 Informa UK Limited, trading as Taylor & Francis Group 2022</rights><rights>2022 Informa UK Limited, trading as Taylor & Francis Group</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c394t-db3b7943217fe76a77aa91453a0f44355dd07bb33506a1f8336fa3e8ead78eb93</citedby><cites>FETCH-LOGICAL-c394t-db3b7943217fe76a77aa91453a0f44355dd07bb33506a1f8336fa3e8ead78eb93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35866240$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Hui</creatorcontrib><creatorcontrib>Wang, Gao-Rui</creatorcontrib><creatorcontrib>Wang, Xin-Ting</creatorcontrib><creatorcontrib>Bai, Yu-Yan</creatorcontrib><creatorcontrib>Yuan, Jin-Feng</creatorcontrib><creatorcontrib>Yang, Liu</creatorcontrib><creatorcontrib>Huang, Fei</creatorcontrib><creatorcontrib>Shi, Hai-Lian</creatorcontrib><creatorcontrib>Wu, Xiao-Jun</creatorcontrib><title>Astragaloside IV ameliorates metabolic disorder in db/db obese mice as a PPARγ antagonist</title><title>Journal of asian natural products research</title><addtitle>J Asian Nat Prod Res</addtitle><description>Metabolic disorder is highly related to obesity, insulin resistance, hypertension, and hyperlipidemia. The present study found that astragaloside IV (ASI) attenuated metabolic disorder related symptoms and modulated hepatic lipid metabolism associated gene mRNA expression in db/db mice. ASI inhibited rosiglitazone-induced adipocyte differentiation of 3T3-L1 cells, and lipid accumulation in palmitic acid (PA)-induced HepG2 cells with down-regulated mRNA expression of lipogenesis-related genes. In addition, it was predicted to bind to the ligand binding domain (LBD) of PPARγ and inhibit its transactivity. Collectively, our study suggested that ASI improves lipid metabolism in obese mice probably through suppressing PPARγ activity.</description><subject>3T3-L1 Cells</subject><subject>Animals</subject><subject>Astragaloside IV</subject><subject>Cell differentiation</subject><subject>db/db mice</subject><subject>Gene expression</subject><subject>Hyperlipidemia</subject><subject>Hypertension</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Lipid metabolism</subject><subject>Lipids</subject><subject>Lipogenesis</subject><subject>metabolic disorder</subject><subject>Metabolic disorders</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Obese</subject><subject>Obesity</subject><subject>Obesity - drug therapy</subject><subject>Obesity - metabolism</subject><subject>Palmitic acid</subject><subject>Peroxisome proliferator-activated receptors</subject><subject>PPAR gamma - genetics</subject><subject>PPAR gamma - metabolism</subject><subject>PPARγ</subject><subject>RNA, Messenger</subject><subject>Rosiglitazone</subject><issn>1028-6020</issn><issn>1477-2213</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kM9q3DAQh0Voaf71EVIEvfTiRNLYknXrEtokEGgoTQ-9iJE1Dgq2lUpeSp4r79Fnipfd9JBDLzNz-H4zw8fYiRSnUrTiTArVaqHEqRJKLcW2Ruk9diBrYyqlJLxZ5oWpNtA-OyzlXgglpVbv2D40rdaqFgfs16rMGe9wSCUG4lc_OY40xJRxpsJHmtGnIXY8xJJyoMzjxIM_C54nT4X4GDviWDjym5vV979PHKcZ79IUy3zM3vY4FHq_60fs9uuXH-eX1fW3i6vz1XXVga3nKnjwxtagpOnJaDQG0cq6ARR9XUPThCCM9wCN0Cj7FkD3CNQSBtOSt3DEPm33PuT0e01ldmMsHQ0DTpTWxSltwRgA2S7ox1fofVrnafnOKWOtVdaaDdVsqS6nUjL17iHHEfOjk8Jt5LsX-W4j3-3kL7kPu-1rP1L4l3qxvQCft0Cc-pRH_JPyENyMj0PKfcapi8XB_288A7XEkmw</recordid><startdate>20230504</startdate><enddate>20230504</enddate><creator>Wu, Hui</creator><creator>Wang, Gao-Rui</creator><creator>Wang, Xin-Ting</creator><creator>Bai, Yu-Yan</creator><creator>Yuan, Jin-Feng</creator><creator>Yang, Liu</creator><creator>Huang, Fei</creator><creator>Shi, Hai-Lian</creator><creator>Wu, Xiao-Jun</creator><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QR</scope><scope>7SN</scope><scope>7T5</scope><scope>7TO</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20230504</creationdate><title>Astragaloside IV ameliorates metabolic disorder in db/db obese mice as a PPARγ antagonist</title><author>Wu, Hui ; Wang, Gao-Rui ; Wang, Xin-Ting ; Bai, Yu-Yan ; Yuan, Jin-Feng ; Yang, Liu ; Huang, Fei ; Shi, Hai-Lian ; Wu, Xiao-Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-db3b7943217fe76a77aa91453a0f44355dd07bb33506a1f8336fa3e8ead78eb93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>3T3-L1 Cells</topic><topic>Animals</topic><topic>Astragaloside IV</topic><topic>Cell differentiation</topic><topic>db/db mice</topic><topic>Gene expression</topic><topic>Hyperlipidemia</topic><topic>Hypertension</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Lipid metabolism</topic><topic>Lipids</topic><topic>Lipogenesis</topic><topic>metabolic disorder</topic><topic>Metabolic disorders</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Obese</topic><topic>Obesity</topic><topic>Obesity - drug therapy</topic><topic>Obesity - metabolism</topic><topic>Palmitic acid</topic><topic>Peroxisome proliferator-activated receptors</topic><topic>PPAR gamma - genetics</topic><topic>PPAR gamma - metabolism</topic><topic>PPARγ</topic><topic>RNA, Messenger</topic><topic>Rosiglitazone</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Hui</creatorcontrib><creatorcontrib>Wang, Gao-Rui</creatorcontrib><creatorcontrib>Wang, Xin-Ting</creatorcontrib><creatorcontrib>Bai, Yu-Yan</creatorcontrib><creatorcontrib>Yuan, Jin-Feng</creatorcontrib><creatorcontrib>Yang, Liu</creatorcontrib><creatorcontrib>Huang, Fei</creatorcontrib><creatorcontrib>Shi, Hai-Lian</creatorcontrib><creatorcontrib>Wu, Xiao-Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Ecology Abstracts</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of asian natural products research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Hui</au><au>Wang, Gao-Rui</au><au>Wang, Xin-Ting</au><au>Bai, Yu-Yan</au><au>Yuan, Jin-Feng</au><au>Yang, Liu</au><au>Huang, Fei</au><au>Shi, Hai-Lian</au><au>Wu, Xiao-Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Astragaloside IV ameliorates metabolic disorder in db/db obese mice as a PPARγ antagonist</atitle><jtitle>Journal of asian natural products research</jtitle><addtitle>J Asian Nat Prod Res</addtitle><date>2023-05-04</date><risdate>2023</risdate><volume>25</volume><issue>5</issue><spage>484</spage><epage>496</epage><pages>484-496</pages><issn>1028-6020</issn><eissn>1477-2213</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Metabolic disorder is highly related to obesity, insulin resistance, hypertension, and hyperlipidemia. The present study found that astragaloside IV (ASI) attenuated metabolic disorder related symptoms and modulated hepatic lipid metabolism associated gene mRNA expression in db/db mice. ASI inhibited rosiglitazone-induced adipocyte differentiation of 3T3-L1 cells, and lipid accumulation in palmitic acid (PA)-induced HepG2 cells with down-regulated mRNA expression of lipogenesis-related genes. In addition, it was predicted to bind to the ligand binding domain (LBD) of PPARγ and inhibit its transactivity. Collectively, our study suggested that ASI improves lipid metabolism in obese mice probably through suppressing PPARγ activity.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>35866240</pmid><doi>10.1080/10286020.2022.2098726</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1028-6020 |
| ispartof | Journal of asian natural products research, 2023-05, Vol.25 (5), p.484-496 |
| issn | 1028-6020 1477-2213 |
| language | eng |
| recordid | cdi_proquest_journals_2799929978 |
| source | Taylor and Francis Science and Technology Collection |
| subjects | 3T3-L1 Cells Animals Astragaloside IV Cell differentiation db/db mice Gene expression Hyperlipidemia Hypertension Insulin Insulin resistance Lipid metabolism Lipids Lipogenesis metabolic disorder Metabolic disorders Mice Mice, Inbred C57BL Mice, Obese Obesity Obesity - drug therapy Obesity - metabolism Palmitic acid Peroxisome proliferator-activated receptors PPAR gamma - genetics PPAR gamma - metabolism PPARγ RNA, Messenger Rosiglitazone |
| title | Astragaloside IV ameliorates metabolic disorder in db/db obese mice as a PPARγ antagonist |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T23%3A01%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Astragaloside%20IV%20ameliorates%20metabolic%20disorder%20in%20db/db%20obese%20mice%20as%20a%20PPAR%CE%B3%20antagonist&rft.jtitle=Journal%20of%20asian%20natural%20products%20research&rft.au=Wu,%20Hui&rft.date=2023-05-04&rft.volume=25&rft.issue=5&rft.spage=484&rft.epage=496&rft.pages=484-496&rft.issn=1028-6020&rft.eissn=1477-2213&rft_id=info:doi/10.1080/10286020.2022.2098726&rft_dat=%3Cproquest_infor%3E2799929978%3C/proquest_infor%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c394t-db3b7943217fe76a77aa91453a0f44355dd07bb33506a1f8336fa3e8ead78eb93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2799929978&rft_id=info:pmid/35866240&rfr_iscdi=true |